Parkinson's Disease Research

Parkinson's disease (PD) is a degenerative disease of the central nervous system that often impairs motor skills, speech, and other functions. Symptoms of the disease include resting tremor, bradykinesia and rigidity. The primary symptoms are the result of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Symptoms of the disease appear once 50-80% of dopamine neurons have died. Parkinson's disease is both chronic and progressive.

Parkinson's Disease Research Products Targets

Products for Parkinson's Disease Research - Page 71

  1. Cat.No. Product Name Information/Activity
  2. BCC7623 (±)-LY 395756 852679-66-4 (±)-LY 395756 chemical structure
  3. BCC6758 MAP4 157381-42-5 MAP4 chemical structure
  4. BCC6925 (RS)-APICA 170847-18-4 (RS)-APICA chemical structure
  5. BCC6871 EGLU EGLU ((2S)-α-Ethylglutamic acid; (2S)-α-EGLU) is a potent and competitive mGluR-2 receptor antagonist. EGLU interacts with (lS,3S)-ACPD-sensitive site with a Kd value of 66 μM. EGLU is an antidepressant agent. EGLU chemical structure
  6. BCC1724 LY341495 LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50s of 2.9 nM, 10 nM, 170 nM for mGluR-2, mGluR-3, mGluR-8, respectively. LY341495 chemical structure
  7. BCC6819 MSPG 169209-64-7 MSPG chemical structure
  8. BCC6820 MTPG 169209-66-9 MTPG chemical structure
  9. BCC7513 Ro 64-5229 246852-46-0 Ro 64-5229 chemical structure
  10. BCC7849 BINA Biphenylindanone A (BINA) is a selective human mGluR2 (hmGluR2) potentiator for the treatment of many neurological disorders. BINA chemical structure
  11. BCC7824 CBiPES hydrochloride 856702-40-4 CBiPES hydrochloride chemical structure

Items 701 to 710 of 752 total